News
1d
TipRanks on MSNCapricor Therapeutics initiated with a Buy at Alliance Global PartnersAlliance Global Partners analyst Matthew Venezia initiated coverage of Capricor Therapeutics (CAPR) with a Buy rating and $20 price target adding a “Speculative” modifier to its rating, calling ...
Alliance Global Partners analyst James Molloy upgraded BioCardia (BCDA) to Buy from Neutral with a $6 price target The company recently announced multiple clinical updates regarding its lead ...
Fintel reports that on August 25, 2023, Alliance Global Partners maintained coverage of PHX Minerals Inc - with a Buy recommendation. Analyst Price Forecast Suggests 46.37% Upside ...
Alliance Global Partners analyst A. Grey expects that the company will earn $1.84 per share for the quarter. Alliance Global Partners ...
Alliance Global Partners put a Buy rating on AirJoule Technologies (AIRJ) with an $8.75 price target following a transfer of coverage. AirJoule is a clean technology company that is focused on ...
Global Partners LP has agreed to buy 100 percent of the membership interests of Alliance Energy LLC in a transaction with an enterprise value of $296 million. Global Partners, a public company ...
The Securities and Exchange Commission has charged Alliance Global Partners with publishing daily quotes at above market prices on between 4,300 and 6,500 different municipal bonds over a two-year ...
Alliance Global Partners initiated coverage of Worksport (WKSP) with a Buy rating and $2 price target Worksport’s primary product is tonneau covers that are designed for pickup trucks and sales ...
Fintel reports that on August 28, 2023, Alliance Global Partners downgraded their outlook for AgileThought Inc – (NASDAQ:AGIL) from Buy to Sell.. Analyst Price Forecast Suggests 1,104.17% Upside ...
Alliance Global Partners raised the firm’s price target on Knot Offshore Partners (KNOP) to $12 from $10 and keeps a Neutral rating on the shares. The firm notes Q4 Operating results were well ...
Alliance Global Partners analyst Scott Henry lowered the firm’s price target on Evogene (EVGN) to $6 from $11.25 and keeps a Buy rating on the shares after the company reported Q4 earnings that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results